[1]
|
Makinen, J., Miettunen, J., Isohanni, M. and Koponen, H. (2008) Negative symptoms in schizophrenia: A review. Nordic Journal of Psychiatry, 62, 334-341.
doi:10.1080/08039480801959307
|
[2]
|
Amminger, G.P., Henry, L.P., Harrigan, S.M., et al. (2011) Outcome in early-onset schizophrenia revisited: Findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophrenia Research, 131, 112-119.
doi:10.1016/j.schres.2011.06.009
|
[3]
|
Shrivastava, A., Johnston, M., Thakar, M., Stitt, L. and Shah, N. (2011) Social outcome in clinically recovered first-episodeschizophrenia in a naturalistic, ten-year, follow-up study in India. Clinical Schizophrenia & Related Psychoses, 5, 95-101. doi:10.3371/CSRP.5.2.6
|
[4]
|
Miller, D., Perry, P., Cadoret, R. and Andreasen, N. (1994) Clozapine’s effect on negative symptoms in treatment-refractory schizophrenia. Comprehensive Psychiatry, 35, 8-15. doi:10.1016/0010-440X(94)90164-3
|
[5]
|
Tandon, R., Nasrallah, H.A. and Keshavan, M.S. (2009) Schizophrenia, “just the facts”: Clinical features and conceptualization. Schizophrenia Research, 110, 1-23.
doi:10.1016/j.schr es.2009.03.005
|
[6]
|
Greenwood, K.E., Landau, S. and Wykes, T. (2005) Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull, 31, 910-921. doi:10.1093/schbul/sbi035
|
[7]
|
Bobes, J., Arango, C., Garcia-Garcia, M. and Rejas, J. (2010) Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. Journal of Clinical Psychiatry, 71, 280-286. doi:10.4088/JCP.08m04250yel
|
[8]
|
Gardner, K.N. and Bostwick, J.R. (2012) Antipsychotic treatment response in schizophrenia. American Journal of Health-System Pharmacy, 69, 1872-1890.
doi:10.2146/ajhp110559
|
[9]
|
Gupta, S., Andreasen, N.C., Arndt, S., et al. (1997) The Iowa longitudinal study of recent onset psychosis: Oneyear follow-up of first episode patients. Schizophrenia Research, 23, 1-13.
doi:10.1016/S0920-9964(96)00078-3
|
[10]
|
Wood, S., Nelson, B., Brewer, W., et al. (2011) Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophrenia Research, 132, 1-7.
doi:10.1016/j.schres.2011.06.014
|
[11]
|
Addington, J., Leriger, E. and Addington, D. (2003) Symptom outcome 1 year after admission to an early psychosis program. Canadian Journal of Psychiatry, 48, 204-207.
|
[12]
|
Husted, J.A., Beiser, M. and Iacono, W.G. (1995) Negative symptoms in the course of first episode affective psychosis. Psychiatry Research, 56, 145-154.
doi:10.1016/0165-1781(94)02576-X
|
[13]
|
Hovington, C. and Lepage, M. (2012) Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Review of Neurotherapeutics, 12, 53-69. doi:10.1586/ern.11.173
|
[14]
|
Nejad, A., Madsen, K., Ebdrup, B., et al. (2011) Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients. The International Journal of Neuropsychopharmacology, 14, 69-82.
|
[15]
|
Lyne, J., O’Donoghue, B., Owens, E., Renwick, L., et al. (2012) Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophrenia Research, 135, 128-133. doi:10.1016/j.schres.2012.01.004
|
[16]
|
O’Donoghue, B., Owens, E., Renwick, L., et al. (2012) Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophrenia Research, 135, 128-133. doi:10.1016/j.schres.2012.01.004
|
[17]
|
Thaker, G.K. (2007) Schizophrenia endophenotypes as treatment targets. Expert Opinion on Therapeutic Targets, 11, 1189-1206. doi:10.1517/14728222.11.9.1189
|
[18]
|
American Psychiatric Association (1994) DSM-IV: Diagnostic and statistical manual of mental disorders. 4th Edition, APA, Washington, DC.
|
[19]
|
Andreasen, N.C. (1983) Scale for Assessment of Negative Symptoms (SANS). University of Iowa Press, Iowa City.
|
[20]
|
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62.
doi:10.1136/jnnp.23.1.56
|
[21]
|
Guy, W. (1976) Clinical Global Impression (CGI) ECDEU assessment manual for psychopharmacology. US Department of Health, Rockville.
|
[22]
|
Peralta, V., Cuesta, M., Martinez-Larrea, A., et al. (2000) Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. American Journal of Psychiatry, 157, 1461-1466.
doi:10.1176/appi.ajp.157.9.1461
|
[23]
|
Lindenmayer, J.P., Bossie, C.A., Kujawa, M., et al. (2008) Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology, 41, 264-270.
|
[24]
|
Chang, W., Christy, L., Jennifer, Y., et al. (2011) Persistent negative symptoms in first-episode schizophrenia: A prospective three-year follow-up study. Schizophrenia Research, 133, 22-28. doi:10.1016/j.schres.2011.09.006
|
[25]
|
Galderisi, S., Mucci, A., Bitter, I., et al. (2012) Persistent negative symptoms in firstepisode patients with schizophrenia: Results from the European FirstEpisodeSchizophrenia Trial. European Neuropsychopharmacology, 12, 224-232.
|
[26]
|
Suzuki, T., Remington, G., Mulsant, B.H., et al. (2012) Defining treatment resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Research, 197, 28-33.
doi:10.1016/j.psychres.2012.02.013
|
[27]
|
Makinen, J., Miettunen, J., Jaaskelainen, E., et al. (2010) Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatry Research, 178, 121-125.
doi:10.1016/j.psychres.2009.05.011
|
[28]
|
Hovington, C.L., Bodnar, M. and Joober, R. (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry, 12, 224.
doi:10.1186/1471-244X-12-224
|
[29]
|
Bobes, J., Arango, C., Garcia-Garcia, M., et al. (2010) Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study. Journal of Clinical Psychiatry, 71, 280-286. doi:10.4088/JCP.08m04250yel
|
[30]
|
Chang, W.C., Hui, C.L., Tang, J.Y., et al. (2012) Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: A 3-year prospective follow-up study. Psychological Medicine, 1-11. doi:10.1017/S0033291712002838
|
[31]
|
Boonstra, N., Klaassen, R. and Sytema, S. (2012) Duration of untreated psychosis and negative symptoms—A systematic review and meta-analysis of individual patient data. Schizophrenia Research, S0920-9964(12)00498-7.
|
[32]
|
Cullen, K., Guimaraes, A., Wozniak, J., et al. (2011) Trajectories of social withdrawal and cognitive decline in the schizophrenia prodrome. Clinical Schizophrenia & Related Psychoses, 4, 229-238. doi:10.3371/CSRP.4.4.3
|
[33]
|
Klaassen, R.M., Velthorst, E., Nieman, D.H., et al. (2011) Factor analysis of the scale of prodromal symptoms: Differentiating between negative and depression symptoms. Psychopathology, 44, 379-385. doi:10.1159/000325169
|
[34]
|
Lin, A., Wood, S.J., Nelson, B., et al. (2011) Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophrenia Research, 132, 1-7.
doi:10.1016/j.schres.2011.06.014
|
[35]
|
Gee, D.G. and Cannon, T.D. (2011) Prediction of conversion to psychosis: Review and future directions. Revista Brasileira de Psiquiatria, 33, 129-142.
|
[36]
|
Sommer, I.E., Begemann, M.J., Temmerman, A., et al. (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull, 38, 1003-1011. doi:10.1093/schbul/sbr004
|
[37]
|
Zink, M., Englisch, S. and Meyer-Lindenberg, A. (2011) Polypharmacy in schizophrenia. Nervenarzt, 82, 853-858.
doi:10.1007/s00115-010-3196-0
|
[38]
|
Englisch, S. and Zink, M. (2012) Treatment-resistant schizophrenia: Evidence-based strategies. Mens Sana Monographs, 10, 20-32. doi:10.4103/0973-1229.91588
|
[39]
|
Himelhoch, S., Slade, E., Kreyenbuhl, J., et al. (2012) Antidepressant prescribing patterns among VA patients with schizophrenia. Schizophrenia Research, 136, 32-35.
doi:10.1016/j.schres.2012.01.008
|
[40]
|
Premkumar, T.S. and Pick, J. (2006) Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews, 4, CD005962.
|
[41]
|
Murphy, B.P., Chung, Y.C., Park, T.W., et al. (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia Research, 88, 5-25. doi:10.1016/j.schres.2006.07.002
|
[42]
|
Fakra, E. and Azorin, J.M. (2012) Clozapine for the treatment of schizohrenia. Expert Opinion on Pharmacotherapy, 13, 1923-1935.
doi:10.1517/14656566.2012.709235
|
[43]
|
Vera, I., Rezende, L., Molina, V., et al. (2012) Clozapine as treatment of first choice in first psychotic episodes. What do we know? Actas Espa?olas de Psiquiatría, 40, 281-289.
|
[44]
|
Moore, T.A., Buchanan, R.W., Buckley, P.F., et al. (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatryiatry, 68, 1751-1762.
doi:10.4088/JCP.v68n1115
|
[45]
|
Levine, S.Z. and Leucht, S. (2013) Attaining and sustaining remission of predominant negative symptoms. Schizophrenia Research, 143, 60-64.
doi:10.1016/j.schres.2012.11.010
|
[46]
|
Herbener, E.S. and Harrow, M. (2001) Longitudinal assessment of negative symptoms inschizophrenia/schizoaffective patients, other psychotic patients, and depressedpatients. Schizophr Bull, 27, 527-537.
doi:10.1093/oxfordjournals.schbul.a006893
|